functional dyspepsia

Acotiamide monohydrochloride trihydrate (Z-338 HCl) is the hydrochloride salt form of acotiamide, a prokinetic agent with gastrointestinal (GI) motility-enhancing activity. Although the exact mechanism by which acotiamide exerts its effect has yet to be fully elucidated, this agent appears to inhibit acetylcholinesterase (AchE), an enzyme responsible for the breakdown of acetylcholine (Ach). Increased Ach concentrations lead to an improvement of gastric emptying and GI motility and eventually to a reduction of dyspepsia symptoms.

Itopride HCl is an AChE inhibitor and dopamine D2 receptor antagonist. It inhibits lower esophageal sphincter relaxation. It also used to treat functional dyspepsia and gastroesophageal reflux disease

R-137696 is an orally active 5-HT1A receptor agonist that facilitates the relaxation of the proximal stomach. It is utilized in research related to functional dyspepsia.

TD-2749 is a selective 5-HT4 agonist discovered by Theravance through multivalent compound design as part of a compound discovery project aimed at finding new treatments for gastrointestinal motility disorders. It is primarily used to treat chronic constipation, constipation-predominant irritable bowel syndrome (C-IBS), opioid-induced constipation, functional dyspepsia, and diabetic gastroparesis.

Arginine glutamate serves as a nitrogen donor in the synthesis of nitric oxide. Arginine glutamate promotes gastric emptying in rats and can be used in research on functional dyspepsia.

Acotiamide is an orally active, selective, and reversible acetylcholinesterase (AChE) inhibitor with an IC50 of 1.79 μM. It is a gastroprokinetic agent that enhances gastric contractility and accelerates delayed gastric emptying, with potential for research in functional dyspepsia involving gastric motility dysfunction and intestinal inflammatory [1] [2] [3].

Cinitapride Monotartrate is a nonselective agonist of 5-HT1 and 5-HT4 receptors and an antagonist of 5-HT2 and dopamine D2 receptors, Cinitapride Monotartrate is widely applied in gastrointestinal research to investigate mechanisms underlying functional dyspepsia and gastroesophageal reflux disease, including modulation of gastrointestinal motility and visceral sensitivity.

Acotiamide hydrochloride is a selective, orally active, reversible acetylcholine ester (AChE) inhibitor (IC50: 1.79 μM) that increases gastric contractility, accelerates delayed gastric emptying, and can be used to study functional dyspepsia and intestinal inflammation in gastric motility disorders.

Bromopride hydrochloride is the salt form of Bromopride, a dopamine D2 receptor blocker. Bromopride exerts is a gastrointestinal prokinetic exploited clinically for the management of motor disorders of the upper gastrointestinal tract, including functional dyspepsia, gastric stasis of various origins and emesis.

Acotiamide Methyl Ether is a metabolite of Acotiamide -- an acetylcholinesterase inhibitor which has been shown to stimulate gastric motility and improve gastric motility dysfunction in rats. Acotiamide Hydrochloride has also been shown to improve meal-related symptoms of functional dyspepsia.

Recanaclotide can be used to treat Gastroparesis, Functional Dyspepsia, and Other Gastrointestinal Disorders.